Antibiotic Use in UTI

Contact Hours: 3

Pharmacology Hours: 3

Author(s):

Amanda Marten MSN, FNP-C

Course Overview

In this course learners will explore guidelines for antibiotic use in UTI, capturing the nurse clinician’s role in prescribing and administration.

Course Outline

  1. Introduction
  2. Definitions
  3. Medication Overview
  4. Considerations for Prescribers
  5. Upcoming Research
  6. Conclusion

Course Outcomes

After completing this course, the learner will rate a 4 out of 5 on the Likert Scale for their ability to:

  1. Differentiate between uncomplicated and complicated UTI.
  2. Differentiate between the classes of antibiotics and their mechanism of action.
  3. Summarize key considerations when prescribing antibiotics for UTI.

Accreditations and Approvals

CE Credit Logo
  • American Nurses Credentialing Center (ANCC) (P0614)
  • California Board of Registered Nursing (CEP 17418)
  • Kentucky Board of Nursing (7-0090)
  • Louisiana State Board of Nursing (58)
  • Florida Board of Nursing (50-23983)
  • Delaware Board of Nursing (DE-24-010127)
  • Alabama Board of Nursing (#ABNP1577)
  • Iowa Board of Nursing (#393)
  • Kansas Board of Nursing (LT0340-0325)

Approved by the Board of Nursing in every state, you can complete your RN, LVN, and APRN CEUs with confidence.

Accreditation Statement

Nursing CE Central LLC is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

It will take the average learner 180 minutes to complete and awards 3 contact hours of continuing education.

Written For

  • Advanced Practice Registered Nurses (APRN)

Requirements for Completion

  1. Enrollment in the course by the learner
  2. Read and learn all course materials
  3. Complete the course evaluation
  4. Attest and testify learning of the course materials

Disclosure of Relevant Financial Relationships

Nursing CE Central nor any of the authors, planners, content experts, or any contributors have any relevant financial relationships with ineligible companies to disclose.